Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2003-09-04
2008-12-30
Afremova, Vera (Department: 1657)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S009100
Reexamination Certificate
active
07470431
ABSTRACT:
The present invention related to methods for treating neurological-urological conditions associated with prostate cancer or methods of treatment of prostate cancer, which is accomplished by administration of botulinum toxin to the patient.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5183462 (1993-02-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6506399 (2003-01-01), Donovan
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6667041 (2003-12-01), Schmidt
patent: 7001602 (2006-02-01), Schmidt
patent: 7153514 (2006-12-01), Schmidt
patent: 2005/0048084 (2005-03-01), Schmidt
patent: 2005/0049175 (2005-03-01), Schmidt
patent: 2005/0112147 (2005-05-01), Schmidt
patent: 2005/0159337 (2005-07-01), Schmidt
patent: 6-183975 (1994-07-01), None
patent: 8-511537 (1996-12-01), None
patent: WO 95/05842 (1995-03-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 99/03483 (1999-01-01), None
“AFUD Prostate Cancer Treatment: Treatment”;American Foundation for Urologic Disease; (at least as early as Aug. 5, 2003).
Bardsley; “The Neurogenic Bladder”;Art&Science Continenece; (Jan. 7, 2000); pp. 39-41.
Burnstein et al.; “Prostatitis: A Difficult Diagnosis”;DeKalb Clinic Urology; (at least as early as Aug. 20, 2003); 3 pp.
Bruschini et al., “Neurologic Control of Prostactic Secretion in the Dog”;Invest. Urol., 15(4):288-290 (Jan. 1978).
“Continence Management”;The Prostate Cancer Charity; (at least as early as Aug. 8, 2003); 6 pp.
Crawford; “Prostate Cancer”;Best Doctors; (Jun. 7, 2000); 6 pp.
Downie et al., “Evidence for a Spinal Site of Action of Clonidine on Somatic and Viscerosomatic Reflex Activity Evoked on the Pudenal Nerve in Cats”;J. Pharmacol. Exp. Ther., 246(1):352-358 (May 1988).
Dykstra et al., “Treatment of Detrusor-Sphincter Dyssynergia with Botulinum A Toxin: A Double-Blind Study”;Arch. Phys. Med. Rehabil., 71:24-26 (Jan. 1990).
Epstein;“Gleason Score 2-4 Adenocarcinoma of the Prostate on Needle Biopsy”;American Journal of Surgical Pathology; (2000) vol. 24(4); pp. 477-78.
H{dot over (a)}kanson et al., “Multiple Tachykinin Pools in Sensory Nerve Fibres in the Rabbit Iris”;Neuroscience, 21(3):943-950 (1987).
Higgins et al., “Studies on the Structure and Intrinsic Innervation of the Normal Human Prostate”;Prostate Suppl., 2:5-16 (1989).
“Inconsistence and the Prostate”;Phoenix5; (at least as early as Aug. 5, 2003); 11 pp.
Ishizuka et al., “Urodynamic Effects of Intravesical Resiniferatoxin and Capsaicin in Conscious Rats With and Without Outflow Obstruction”;J. Urology, 154:611-616 (Aug. 1995).
Joo et al., “Initial North American Experience with Botulinum Toxin Type A for Treatmetn of Anismus”;Dis. Colon. Rectum, 39(10):1107-1111 (Oct. 1996).
Lepor “Role of Long-Acting Selective Alpha-1 Blockers in the Treatment of Benign Prostatic Hyperplasia”;Urol. Clin. North Am., 17(3):651-658 (Aug. 1990).
Maggi et al., “Cystometric Evidence That Capsaicin-Sensitive Nerves Modulate the Afferent Branch of Micturition Reflex in Human”;J. Urol., 142:150-154 (Jul. 1989).
Marieb; “Chapter 13: Peripheral Nervous System and Reflux Activity”;Human Anatomy and Physiology, 5thEd.; (at least as early as Aug. 8, 2003) 5 pp.
Mocchetti, “Pharmacology and Neuronal Gene Expression”;Pharmacol. Res., 21(Suppl. 2):85-95 (1989).
Peak; “Understanding Continence”;The Interdisciplinary Journal of Rehabilitation; (Mar. 2002); 9 pp.
“Prostate Cancer: Prostate Cancer Transrectal Biopsies”; (at least as early as Aug. 20, 2003); 9 pp.
“Prostate Cancer: Tumor Grading”;UPMC Cancer Centers; (2003); 2 pp.
“Prostate Cancer: What are the Treatment Options?”;NSW Health; (Jan. 4, 2002); 2 pp.
“Prostate Cancer (PDQ®): Treatment”;National Cancer Institute; (Jul. 17, 2003); 11 pp.
“Prostate Gland and Urinary Problems”;Better Health Channel; (Oct. 10, 2001); 10 pp.
Schurch et al.,J. Urol., 155:1023-1029 (1996).
Strum; “Is There a Correct Way to Treat Prostate Cancer”;Prostate Cancer Research Institute; 28 pp. (at least as early as Sep. 12, 2000).
Strum; “Predictive and Prognostic Information in the Counseling of Patients Recently Diagnosed with Prostate Cancer”;The Prostate Cancer Research Institute; (at least as early as Sep. 12, 2000); 21 pp.
“The Side Effects of Treatment”;Varian Medical System; (1999-2033); 2 pp.
Tim et al.,Botulinum Toxin Therapy, 9(6):327-332 (1992).
“Treating Prostate Disease”;The Cleveland Clinic; (Jan. 28, 1999); 3 pp.
“Treatment for Localized Disease: Observation and Monitoring of PSA”;Prostate Cancer Research Institute; (at least as early as Aug. 11, 2003); 1 p.
“Questions and Answers About the Prostate-Specific Antigen (PSA) Test”;National Cancer Institute; (Jan. 11, 2001); 5 pp.
“Understanding Gleason Grading”;Phoenix5; (May 14, 1997); 8 pp.
Beleggia et al., Arch. It. Urol., LXIX, (S.1): 61-63, 1997 (English Abstract).
Chancellor et al., J Urol Apr. 2003;169 (Supp 4):351.
DasGupta et al., Urogynaecology 2003, 13:293-299.
Fowler et al., British J Urol., Oct. 22, 1991, 387-389.
Kuo, Hann-Chorng, J Urol Nov. 2003, 170:1908-1912.
Leippold et al., Eur Urol 44 (2003) 165-174.
Nanninga, John B., Oxins (1993) p. 589-590.
Smith et al., Int Urogynecol J (2002) 13:55-56.
Amarenco, Pour la pratique, Lae Revue du Praticien (Paris), 1995, 343-345, 45, France and abstract in English.
Araki et al. Detrusor-Sphincter Dyssynergia with Special Reference to its Diagnosis and Treatment, J. Saitama Med. School, 1992, 23-27, vol. 19, Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama Med. School, 1992, 23-27, vol. 19, Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama, Japan.
Bulau, Therapeautische Perspektiven mit Botulinumtoxin Type A., Neurologie und rehabilitation, 1997,.55-56, Germany.
Doggweiler et al., Botox-Induced Prostatic Involution, The Prostate, 1998, 44-50, vol. 37, University of Colorado Health Science Center, Denver, CO, USA.
Dykstra et al., Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients, J Urol, May 1998, 919-922, vol. 139, Departments of Physical Medicine and Rahbilitation and Urologic Surgery, Univeristy of Minnesota Hospital and Clinic, Minneapolis Minnesota, USA.
Fowler et al., Mytonic-Like EMG Activity of the Urethral Sphincter in Women with Urinary Retention and the Use of Botulinum Toxin to Treat this Disorder, Neurophysiologie Clinique, 1990, 19s, vol. 20, Department of Uro-Neurology, National Hospital for Nervous Diseases, Queen Square and Urology Departments, The London Hospital and the Middlesex Hospital United Kingdom.
Fowler et al., Botulinum Toxin in the Treatment of Chronic Urinary Retention in Women, British Journal of Urology, 1992, 387-389, vol. 70, British Journal of Urology, United Kingdom.
Maria et al., Relief by botulinum toxin of voiding dysfunction due to prostatis, Lancet (North American Edition), 1998, 625, vol. 352, Departments of Surgery, Urology and Neurology, Catholic University of Rome, Rome, USA.
Harrison, Principles of Internal Medicine, 1987, 196-197, 11th Edition, McGraw-Hill Book Company, New York, New York, USA.
Jankovic, Botulinum toxin in movement disorders, Current Opinion in Neurology, 1994, 358-366, vol. 7, Baylor College of Medicine, Houston, Texas, USA.
Jankovic, Therapeutic uses of Botulinum, The New England Jou
Schmidt Richard A.
The Regents of the University of Colorado, legal representative The Regents of the University of Colorado, legal representative
Afremova Vera
Sheridan & Ross P.C.
The Regents of the University of Colorado
LandOfFree
Use of neurotoxin therapy for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of neurotoxin therapy for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of neurotoxin therapy for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046049